NewGenIvf Group Limited Class A Ordinary Shares (NIVF) - Net Assets
Based on the latest financial reports, NewGenIvf Group Limited Class A Ordinary Shares (NIVF) has net assets worth $25.99 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($32.72 Million) and total liabilities ($6.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of NewGenIvf Group Limited Class A Ordinary to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $25.99 Million |
| % of Total Assets | 79.41% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7750.12 |
NewGenIvf Group Limited Class A Ordinary Shares - Net Assets Trend (2021–2025)
This chart illustrates how NewGenIvf Group Limited Class A Ordinary Shares's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see NIVF stock market capitalisation.
Annual Net Assets for NewGenIvf Group Limited Class A Ordinary Shares (2021–2025)
The table below shows the annual net assets of NewGenIvf Group Limited Class A Ordinary Shares from 2021 to 2025. Also explore NIVF year-over-year net asset growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $25.99 Million | +1853.78% |
| 2024-12-31 | $-1.48 Million | -109.50% |
| 2023-12-31 | $15.60 Million | +15390.73% |
| 2022-12-31 | $100.68K | +111.00% |
| 2021-12-31 | $-914.91K | -- |
Equity Component Analysis
This analysis shows how different components contribute to NewGenIvf Group Limited Class A Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 994362500.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $8.89 Million | 33.39% |
| Other Comprehensive Income | $-143.07K | -0.54% |
| Other Components | $17.88 Million | 67.14% |
| Total Equity | $26.63 Million | 100.00% |
NewGenIvf Group Limited Class A Ordinary Shares Competitors by Market Cap
The table below lists competitors of NewGenIvf Group Limited Class A Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Candela Invest SA
BR:CAND
|
$2.15 Million |
|
Braille Energy Systems Inc
V:BES
|
$2.15 Million |
|
Lucapa Diamond Co Ltd
F:NHY
|
$2.15 Million |
|
Stinger Resources Inc
V:STNG
|
$2.15 Million |
|
Plaza Centers NV
WAR:PLZ
|
$2.15 Million |
|
Clearside Biomedical Inc
NASDAQ:CLSD
|
$2.15 Million |
|
Aptevo Therapeutics Inc
NASDAQ:APVO
|
$2.14 Million |
|
Australian Bond Exchange Holdings Ltd
AU:ABE
|
$2.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NewGenIvf Group Limited Class A Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,048,614 to 26,631,519, a change of 27,680,133.
- Net income of 9,879,408 contributed positively to equity growth.
- New share issuances of 12,620,496 increased equity.
- Other comprehensive income decreased equity by 161,946.
- Other factors increased equity by 5,342,175.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $9.88 Million | +37.1% |
| Share Issuances | $12.62 Million | +47.39% |
| Other Comprehensive Income | $-161.95K | -0.61% |
| Other Changes | $5.34 Million | +20.06% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares NewGenIvf Group Limited Class A Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-8.88 | $0.78 | x |
| 2022-12-31 | $6.44 | $0.78 | x |
| 2023-12-31 | $2.87 | $0.78 | x |
| 2024-12-31 | $-5.35 | $0.78 | x |
| 2025-12-31 | $135.82 | $0.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NewGenIvf Group Limited Class A Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 37.10%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 209.02%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.23x
- Recent ROE (37.10%) is above the historical average (22.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -0.01% | 2.91x | 0.00x | $77.06K |
| 2022 | 81.45% | 7.72% | 2.05x | 5.16x | $402.36K |
| 2023 | -4.43% | -13.45% | 0.24x | 1.37x | $-2.25 Million |
| 2024 | 0.00% | -9.66% | 1.52x | 0.00x | $-420.14K |
| 2025 | 37.10% | 209.02% | 0.14x | 1.23x | $7.22 Million |
Industry Comparison
This section compares NewGenIvf Group Limited Class A Ordinary Shares's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $280,588,546
- Average return on equity (ROE) among peers: 3.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NewGenIvf Group Limited Class A Ordinary Shares (NIVF) | $25.99 Million | 0.00% | 0.26x | $2.15 Million |
| Acadia Healthcare Company Inc (ACHC) | $96.36 Million | -36.21% | 3.29x | $1.52 Billion |
| Addus HomeCare Corporation (ADUS) | $175.08 Million | 7.77% | 0.53x | $1.69 Billion |
| agilon health Inc (AGL) | $-232.03 Million | 0.00% | 0.00x | $1.51 Billion |
| Airsculpt Technologies Inc (AIRS) | $120.39 Million | -1.84% | 0.42x | $151.76 Million |
| Amedisys Inc (AMED) | $641.51 Million | 19.77% | 0.97x | $3.32 Billion |
| AMN Healthcare Services Inc (AMN) | $193.20 Million | 11.51% | 2.20x | $624.22 Million |
| American Shared Hospital Service (AMS) | $20.85 Million | 8.48% | 1.33x | $8.87 Million |
| American Oncology Network Inc. (AONC) | $226.04 Million | -0.05% | 0.10x | $325.24 Million |
| Ardent Health Partners, Inc. (ARDT) | $1.05 Billion | 17.99% | 3.63x | $1.54 Billion |
| Astrana Health Inc (ASTH) | $514.17 Million | 8.39% | 1.64x | $1.87 Billion |
About NewGenIvf Group Limited Class A Ordinary Shares
NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company provides a range of fertility treatment solutions, including in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screen… Read more